Recent Updates
Recently added Catalysts
BLFS Positive Sentiment Score: 70/100

BioLife Solutions Announces the Sale of its evo Cold Chain Logistics Subsidiary

Key Takeaway: BioLife Solutions, Inc. has announced the sale of its cold chain logistics subsidiary, SAVSU Cleo Technologies, for $25.5 million in cash to Peli BioThermal. This divestiture aims to streamline BioLife's product portfolio and operations, allowing the company to focus on generating high-margin recurring revenue. CEO Roderick de Greef expressed satisfaction with the transaction, highlighting the value of SAVSU's technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful sale of SAVSU subsidiary for $25.5 million.
  • Streamlining of product portfolio to enhance operational focus.
  • Focus on high-margin recurring revenue to create shareholder value.
  • Recognition of SAVSU technology's value by a respected logistics leader.

Full Press Release Details

BOTHELL, Wash.,Oct. 7, 2025/PRNewswire/ --BioLife Solutions, Inc.(Nasdaq:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene therapy ("CGT") market, announces the sale of SAVSU Cleo Technologies, LLC. (f/k/a SAVSU Technologies, Inc.) ("SAVSU"), its wholly owned cold chain logistics subsidiary, for $25.5 million (subject to certain adjustments) in cash to Peli BioThermal, a global leader in temperature-controlled logistics solutions.

Roderick de Greef, Chairman and CEO commented "This divestiture streamlines our product portfolio as well as our operations while focusing resources on creating shareholder value through high-margin recurring revenue. We are delighted that a respected leader in cold chain logistics recognizes the value of the SAVSU evo technology."

About BioLife Solutions

BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. For more information, please visitwww.biolifesolutions.com, and follow BioLife onLinkedInandX.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "intend," "expects," "continue," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available atwww.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof, or to reflect any change in our expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Media & Investor Relations

At the Company
Troy WichtermanChief Financial Officer(425) 402-1400[email protected]
Investors
Alliance Advisors IRJody Cain(310) 691-7100[email protected]
SOURCE BioLife Solutions, Inc.

Frequently Asked Questions

What subsidiary did BioLife Solutions sell?

BioLife Solutions sold its cold chain logistics subsidiary, SAVSU Cleo Technologies.

How much was the sale of SAVSU worth?

The sale of SAVSU was valued at $25.5 million in cash.

Who purchased SAVSU from BioLife Solutions?

SAVSU was purchased by Peli BioThermal, a leader in temperature-controlled logistics.

What is the goal of this divestiture?

The divestiture aims to streamline BioLife's product portfolio and focus on high-margin revenue.

Last updated: Oct 7, 2025